LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Suletud

SektorTervishoid

3.55 -0.56

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.5

Max

3.81

Põhinäitajad
By Trading Economics
Sissetulek	-9.9M -48M
Müük	1.8M 13M
Aktsiakasum	-0.21
Kasumimarginaal	-362.728
Töötajad	144
EBITDA	-10M -45M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+196.83% upside

Turustatistika
By TradingEconomics
Turukapital	330M 877M
Eelmine avamishind	4.11
Eelmine sulgemishind	3.55

Uudiste sentiment

By Acuity

29%

71%

87 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. dets 2025, 23:50 UTC

Kuumad aktsiad

Stocks to Watch: Micron, MillerKnoll, HireQuest, Insmed

17. dets 2025, 23:20 UTC

Tulu

Correction to Micron Logs Sales Jump Article

17. dets 2025, 23:07 UTC

Tulu

Micron Logs Sales Jump, Sees Further Growth as AI Demand Outpaces Supply -- Update

17. dets 2025, 21:37 UTC

Tulu

Micron Technology 1Q Sales Jump 57%, Led By Memory Growth

17. dets 2025, 23:53 UTC

Market Talk

Gold Edges Higher, Supported by Some Tailwinds -- Market Talk

17. dets 2025, 23:43 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

17. dets 2025, 23:06 UTC

Omandamised, ülevõtmised, äriostud

Asahi Group: Transaction Expected to Be Closed in 2H of Calendar Year 2026

17. dets 2025, 23:05 UTC

Omandamised, ülevõtmised, äriostud

Asahi Group: Currently No Plans of Issuing New Shares in Asahi

17. dets 2025, 23:04 UTC

Omandamised, ülevõtmised, äriostud

Asahi Group: Funds to Be Provided Via Borrowings From Financial Institutions or Cash on Hand

17. dets 2025, 23:03 UTC

Omandamised, ülevõtmised, äriostud

Asahi Group: Acquisition of 53.68% Stake in UDV (Kenya) is $646M on Equity Value Basis

17. dets 2025, 23:02 UTC

Omandamised, ülevõtmised, äriostud

Asahi Group: Acquisition of 100% Stake in Diageo Kenya is $2.354B on Equity Value Basis

17. dets 2025, 22:59 UTC

Omandamised, ülevõtmised, äriostud

Asahi Group: Deal Part of Strategy Under Medium- to Long-Term Management Policy

17. dets 2025, 22:57 UTC

Omandamised, ülevõtmised, äriostud

Asahi Group: To Indirectly Acquire 65.00% Stake in East African Breweries PLC

17. dets 2025, 22:56 UTC

Omandamised, ülevõtmised, äriostud

Asahi Group: Stakes Acquired From Two Subsidiaries of Diageo Plc

17. dets 2025, 22:55 UTC

Omandamised, ülevõtmised, äriostud

Asahi Group Holdings: To Acquire 100% Stake in Diageo Kenya Ltd., 53.68% Stake in UVD (Kenya) Ltd.

17. dets 2025, 22:49 UTC

Market Talk

Sandfire Resources Production Pipeline Strength Questioned -- Market Talk

17. dets 2025, 21:58 UTC

Tulu

Micron Crushes Earnings. The Stock Is Rising. -- Barrons.com

17. dets 2025, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

17. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. dets 2025, 21:46 UTC

Tulu

Salesforce and Other AI Stocks That Can Catch Up to the Pack -- Barrons.com

17. dets 2025, 21:20 UTC

Tulu

Micron Crushes Earnings. The Stock Is Rising. -- Barrons.com

17. dets 2025, 21:10 UTC

Tulu

Micron Beats Earnings. The Stock Is Rising. -- Barrons.com

17. dets 2025, 21:05 UTC

Tulu

Micron Technology Anticipates Business Performance to Continue Strengthening Through FY26

17. dets 2025, 21:04 UTC

Tulu

Micron Technology: 2Q Outlook Reflects Substantial Records Across Rev, Gross Margin, EPS and Free Cash Flow >MU

17. dets 2025, 21:04 UTC

Tulu

Micron Technology Sees 2Q Oper Expenses $1.56B, Plus or Minus $20M >MU

17. dets 2025, 21:03 UTC

Tulu

Micron Technology Sees 2Q Adj EPS $8.42, Plus or Minus 20c >MU

17. dets 2025, 21:03 UTC

Tulu

Micron Technology Sees 2Q EPS $8.19, Plus or Minus 20c >MU

17. dets 2025, 21:03 UTC

Tulu

Micron Technology Sees 2Q Revenue $18.7B, Plus or Minus $400M >MU

17. dets 2025, 21:02 UTC

Tulu

Micron Technology 1Q Operating Cash Flow $8.41 B >MU

17. dets 2025, 21:01 UTC

Tulu

Micron Technology 1Q Rev $13.64B >MU

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

196.83% tõus

12 kuu keskmine prognoos

Keskmine 11.25 USD 196.83%

Kõrge 15 USD

Madal 8 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

87 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.